Endocrinology

Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

Phenomix will showcase new data on prediction of adverse events to GLP-1 RA therapy, a new obesity sub-phenotype, and approaches to improve surgical outcomes.

Your daily dose of the clinical news you may have missed.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.

Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Your daily dose of the clinical news you may have missed.

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

Data from the phase 2 VENTURE-Oral Dosing Trial of VK2735 is expected in the second half of the year, the company said.

Your daily dose of the clinical news you may have missed.

The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.

The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.

Three of the 5 osteoporosis screening tools recommended by the USPSTF for identifying osteoporosis in postmenopausal women aged 50 yo 64 years proved suboptimal.

The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.